Identification

Name
Alclofenac
Accession Number
DB13167
Type
Small Molecule
Groups
Approved, Withdrawn
Description

Alclofenac is a non-steroidal anti-inflammatory drug. It was withdrawn from the market in the United Kingdom in 1979.

Structure
Thumb
Synonyms
  • (4-Allyloxy-3-chlorphenyl)essigsäure
  • [4-(allyloxy)-3-chlorophenyl]acetic acid
  • 3-Chloro-4-(2-propenyloxy)benzeneacetic acid
  • Alclofénac
  • Alclofenaco
  • Alclofenacum
  • Alclophenac
External IDs
MY-101 / W 7320 / W-7320
International/Other Brands
Allopydin / Epinal / Medifenac / Mervan / Neosten / Neoston / Prinalgin / Reufenac / Zumaril
Categories
UNII
M9CP5H21N8
CAS number
22131-79-9
Weight
Average: 226.66
Monoisotopic: 226.0396719
Chemical Formula
C11H11ClO3
InChI Key
ARHWPKZXBHOEEE-UHFFFAOYSA-N
InChI
InChI=1S/C11H11ClO3/c1-2-5-15-10-4-3-8(6-9(10)12)7-11(13)14/h2-4,6H,1,5,7H2,(H,13,14)
IUPAC Name
2-[3-chloro-4-(prop-2-en-1-yloxy)phenyl]acetic acid
SMILES
OC(=O)CC1=CC(Cl)=C(OCC=C)C=C1

Pharmacology

Indication

Alclofenac is indicated in rheumatology, in particular for the treatment of rheumatoid arthritis, ankylosing spondylitis and, as an analgesic, in painful arthritic pathologies.

Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action

Alclofenac is an inhibitor of prostaglandin H2 synthase. The inhibition of the enzyme occurs through the reversible block of cyclooxygenase enzyme. Therefore, it prevents the production of inflammatory mediators (and pain) as prostacyclins and prostaglandins. Aclofenac has the ability to inhibit the biosynthesis of prostaglandins which may be an important factor in the action of these drugs, but in addition, the effect of these agents in displacing endogenous anti-inflammatory substances from plasma protein binding sites is thought to be an equally important effect in their mechanism of action

TargetActionsOrganism
AProstaglandin G/H synthase 2
antagonist
Human
Absorption

The absorption of alclofenac from the gastrointestinal tract is irregular. After oral or rectal administration maximum plasma concentrations are reached within 1-4 hours.

Volume of distribution

The volume of distribution is 0.1 L / kg

Protein binding

The binding to plasma proteins is 90-99%.

Metabolism

the main metabolic product is alclofenac itself and alclofenac glucuronide

Route of elimination

Alclofenac is excreted in the urine mainly as glucuronide and as unchanged active substance.

Half life

The plasma half-life varies between 1.5 and 5.5 hours.

Clearance

For oral dose of 500mg: Renal clearance constant (av) 35ml/min Overall clearance constant (av) 37-69ml/min

Toxicity

The lethal dose orally: 1100 (mice), 1050 (rats) mg / kg ;
under the skin: 600 (mice), 630 (rats) mg / kg intraperitoneally: 550 (mice), 530 (rats) mg / kg

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Alclofenac is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Alclofenac is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Alclofenac is combined with 5-androstenedione.Experimental, Illicit
AbciximabAlclofenac may increase the anticoagulant activities of Abciximab.Approved
AcebutololAlclofenac may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Alclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Alclofenac is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolAlclofenac may increase the anticoagulant activities of Acenocoumarol.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Alclofenac.Approved, Vet Approved
AclarubicinAlclofenac may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Alclofenac.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Alclofenac is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Alclofenac is combined with Aldosterone.Experimental, Investigational
AldoxorubicinAlclofenac may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level.Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Alclofenac is combined with Alendronic acid.Approved
AliskirenAlclofenac may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Alclofenac is combined with Alminoprofen.Experimental
AlprenololAlclofenac may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Alclofenac.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Alclofenac is combined with Amcinonide.Approved
AmikacinAlclofenac may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideAlclofenac may decrease the antihypertensive activities of Amiloride.Approved
AmrubicinAlclofenac may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodAlclofenac may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Alclofenac.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Alclofenac is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Alclofenac is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Alclofenac is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Alclofenac.Investigational
AnnamycinAlclofenac may decrease the excretion rate of Annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Alclofenac.Approved
Antithrombin III humanAlclofenac may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanAlclofenac may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Alclofenac.Investigational
ApramycinAlclofenac may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Alclofenac.Approved, Investigational
ArbekacinAlclofenac may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinAlclofenac may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanAlclofenac may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololAlclofenac may decrease the antihypertensive activities of Arotinolol.Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Alclofenac is combined with Atamestane.Investigational
AtenololAlclofenac may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Alclofenac.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Alclofenac.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Alclofenac.Approved
BalsalazideAlclofenac may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminAlclofenac may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Alclofenac is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololAlclofenac may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinAlclofenac may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Alclofenac.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Alclofenac.Approved
BenorilateThe risk or severity of adverse effects can be increased when Alclofenac is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Alclofenac.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Alclofenac is combined with Benzydamine.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Alclofenac.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Alclofenac is combined with Betamethasone.Approved, Vet Approved
BetaxololAlclofenac may decrease the antihypertensive activities of Betaxolol.Approved
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Alclofenac.Approved, Investigational
BevantololAlclofenac may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Alclofenac is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Alclofenac.Approved, Investigational
BisoprololAlclofenac may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinAlclofenac may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololAlclofenac may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Alclofenac.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Alclofenac.Investigational
BucindololAlclofenac may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Alclofenac is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Bufexamac.Experimental
BufuralolAlclofenac may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Alclofenac is combined with Bumadizone.Experimental
BumetanideAlclofenac may decrease the diuretic activities of Bumetanide.Approved
BupranololAlclofenac may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Alclofenac.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Alclofenac.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Alclofenac.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Alclofenac.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Alclofenac is combined with Carbaspirin calcium.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Alclofenac.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Alclofenac.Approved, Vet Approved, Withdrawn
CarteololAlclofenac may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolAlclofenac may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Alclofenac.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Alclofenac.Approved, Investigational
CeliprololAlclofenac may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinAlclofenac may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Alclofenac.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Alclofenac.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Alclofenac.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Alclofenac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Alclofenac.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Alclofenac is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Alclofenac.Approved
CinoxacinAlclofenac may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
Citric AcidAlclofenac may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Alclofenac is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Alclofenac is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Alclofenac is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Alclofenac is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Alclofenac is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Alclofenac.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Alclofenac.Vet Approved
CloranololAlclofenac may decrease the antihypertensive activities of Cloranolol.Experimental
ColesevelamColesevelam can cause a decrease in the absorption of Alclofenac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Alclofenac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Alclofenac is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Alclofenac is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Alclofenac is combined with Cortisone acetate.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Alclofenac.Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Alclofenac.Experimental
CyclosporineAlclofenac may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateAlclofenac may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinAlclofenac may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidAlclofenac may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanAlclofenac may increase the anticoagulant activities of Darexaban.Investigational
DaunorubicinAlclofenac may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Alclofenac is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Alclofenac is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Delapril is combined with Alclofenac.Experimental
DesirudinAlclofenac may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Alclofenac is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Alclofenac is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Alclofenac is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Alclofenac is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Alclofenac is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Alclofenac is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Alclofenac is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Alclofenac.Approved, Investigational
DextranAlclofenac may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Alclofenac may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Alclofenac may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Alclofenac may increase the anticoagulant activities of Dextran 75.Approved
DibekacinAlclofenac may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Alclofenac.Approved, Vet Approved
DicoumarolAlclofenac may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Alclofenac is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Alclofenac is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Alclofenac.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Alclofenac is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Alclofenac is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Alclofenac.Approved
DihydrostreptomycinAlclofenac may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Alclofenac.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Alclofenac.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Alclofenac.Approved
DoxorubicinAlclofenac may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneAlclofenac may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Alclofenac.Withdrawn
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Alclofenac.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Alclofenac.Investigational
Edetic AcidAlclofenac may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanAlclofenac may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Alclofenac.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Alclofenac.Approved
EnoxacinAlclofenac may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinAlclofenac may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Alclofenac.Experimental
EpanololAlclofenac may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Alclofenac.Approved
EpirubicinAlclofenac may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneAlclofenac may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Alclofenac.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Alclofenac.Approved
EquileninThe risk or severity of adverse effects can be increased when Alclofenac is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Alclofenac is combined with Equilin.Approved
EsmololAlclofenac may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Alclofenac is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Alclofenac is combined with Estrone sulfate.Approved
Etacrynic acidAlclofenac may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Alclofenac.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Alclofenac is combined with Ethenzamide.Experimental
Ethyl biscoumacetateAlclofenac may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Alclofenac is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Alclofenac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Alclofenac.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Alclofenac.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Alclofenac.Approved, Investigational
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Alclofenac.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Alclofenac.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Alclofenac.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Alclofenac.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Alclofenac.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Alclofenac is combined with Feprazone.Experimental
Ferulic acidAlclofenac may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Alclofenac.Approved, Investigational
FleroxacinAlclofenac may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Alclofenac.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Alclofenac is combined with Fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Alclofenac is combined with Fludrocortisone.Approved
FluindioneAlclofenac may increase the anticoagulant activities of Fluindione.Investigational
FlumequineAlclofenac may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Alclofenac is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Alclofenac is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Alclofenac.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Alclofenac is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Alclofenac is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Alclofenac is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Alclofenac is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Alclofenac is combined with Fluorometholone.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Alclofenac is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Alclofenac is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Alclofenac.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Alclofenac is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Alclofenac.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Alclofenac is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Alclofenac is combined with Fluticasone propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Alclofenac.Approved, Nutraceutical, Vet Approved
FondaparinuxAlclofenac may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumAlclofenac may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Alclofenac.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Alclofenac is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Alclofenac.Approved
FramycetinAlclofenac may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideAlclofenac may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexateAlclofenac may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinAlclofenac may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinAlclofenac may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Alclofenac.Approved, Withdrawn
GemifloxacinAlclofenac may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinAlclofenac may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinAlclofenac may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AAlclofenac may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GPX-150Alclofenac may decrease the excretion rate of GPX-150 which could result in a higher serum level.Investigational
GrepafloxacinAlclofenac may increase the neuroexcitatory activities of Grepafloxacin.Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Alclofenac is combined with Guacetisal.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Alclofenac is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Alclofenac is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Alclofenac is combined with HE3286.Investigational
HeparinAlclofenac may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Alclofenac.Investigational
HydralazineAlclofenac may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Alclofenac.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Alclofenac is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Alclofenac.Approved, Investigational
Hygromycin BAlclofenac may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Alclofenac is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Alclofenac.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Alclofenac.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Alclofenac.Approved
IdarubicinAlclofenac may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdraparinuxAlclofenac may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Alclofenac.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Alclofenac.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Alclofenac is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Alclofenac.Approved
IndenololAlclofenac may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Alclofenac.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Alclofenac.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Alclofenac.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Alclofenac.Approved, Investigational
IsepamicinAlclofenac may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Alclofenac.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Alclofenac is combined with Istaroxime.Investigational
KanamycinAlclofenac may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Alclofenac.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Alclofenac.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Alclofenac.Approved
LabetalolAlclofenac may decrease the antihypertensive activities of Labetalol.Approved
LandiololAlclofenac may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Alclofenac.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Alclofenac.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Alclofenac.Approved, Investigational
LepirudinAlclofenac may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanAlclofenac may increase the anticoagulant activities of Letaxaban.Investigational
LevobunololAlclofenac may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinAlclofenac may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Alclofenac.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Alclofenac.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Alclofenac.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Alclofenac.Approved
LonazolacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Alclofenac.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Alclofenac.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Alclofenac is combined with Loteprednol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Alclofenac.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Alclofenac.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Alclofenac.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Alclofenac.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Alclofenac.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Alclofenac.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Alclofenac is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Alclofenac.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Alclofenac is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Alclofenac.Approved
MelagatranAlclofenac may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Alclofenac is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Alclofenac.Approved, Vet Approved
MepindololAlclofenac may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineAlclofenac may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Alclofenac.Investigational, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Alclofenac.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Alclofenac.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Alclofenac is combined with Methylprednisolone.Approved, Vet Approved
MetipranololAlclofenac may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Alclofenac.Approved
MetoprololAlclofenac may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideAlclofenac may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MicronomicinAlclofenac may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Alclofenac.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Alclofenac.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Alclofenac.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Alclofenac is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Alclofenac is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Alclofenac.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Alclofenac.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Alclofenac.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Alclofenac.Approved
NadololAlclofenac may decrease the antihypertensive activities of Nadolol.Approved
NadroparinAlclofenac may increase the anticoagulant activities of Nadroparin.Approved
NafamostatAlclofenac may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Alclofenac.Approved
Nalidixic AcidAlclofenac may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Alclofenac.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Alclofenac is combined with NCX 1022.Investigational
NeamineAlclofenac may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololAlclofenac may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NemonoxacinAlclofenac may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinAlclofenac may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Alclofenac.Approved
NetilmicinAlclofenac may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Alclofenac is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Alclofenac.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Alclofenac.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Alclofenac.Investigational
NorfloxacinAlclofenac may increase the neuroexcitatory activities of Norfloxacin.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Alclofenac is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Alclofenac.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Alclofenac.Approved
OlsalazineAlclofenac may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of can be d when Alclofenac is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Alclofenac.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Alclofenac.Vet Approved
OtamixabanAlclofenac may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Alclofenac.Approved
Oxolinic acidAlclofenac may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololAlclofenac may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Alclofenac.Approved, Withdrawn
PamidronateThe risk or severity of adverse effects can be increased when Alclofenac is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Alclofenac is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Alclofenac.Approved
ParomomycinAlclofenac may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Alclofenac.Investigational
PazufloxacinAlclofenac may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinAlclofenac may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololAlclofenac may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateAlclofenac may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateAlclofenac may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Alclofenac.Approved
PhenindioneAlclofenac may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonAlclofenac may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Alclofenac.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Alclofenac.Approved, Investigational
PindololAlclofenac may decrease the antihypertensive activities of Pindolol.Approved
Pipemidic acidAlclofenac may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PirarubicinAlclofenac may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideAlclofenac may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Alclofenac.Approved, Investigational
Piromidic acidAlclofenac may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Alclofenac.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Alclofenac is combined with Pirprofen.Experimental
Platelet Activating FactorAlclofenac may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinAlclofenac may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PlicamycinAlclofenac may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Investigational, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Alclofenac.Approved
PractololAlclofenac may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Alclofenac.Approved
PranoprofenThe risk or severity of adverse effects can be increased when Alclofenac is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Alclofenac is combined with Prasterone.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Alclofenac is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Alclofenac is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Alclofenac is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Alclofenac is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Alclofenac is combined with Pregnenolone.Experimental, Investigational
ProbenecidThe serum concentration of Alclofenac can be increased when it is combined with Probenecid.Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Alclofenac is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Alclofenac.Approved, Investigational
PropranololAlclofenac may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Alclofenac is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Alclofenac is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Alclofenac.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Alclofenac.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Alclofenac.Vet Approved
Protein CAlclofenac may increase the anticoagulant activities of Protein C.Approved
Protein S humanAlclofenac may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeAlclofenac may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinAlclofenac may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Alclofenac.Investigational
PuromycinAlclofenac may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Alclofenac.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Alclofenac.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Alclofenac.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Alclofenac.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Alclofenac.Approved, Experimental, Investigational
ReviparinAlclofenac may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinAlclofenac may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Alclofenac is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Alclofenac is combined with Risedronate.Approved, Investigational
RivaroxabanAlclofenac may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Alclofenac.Investigational, Withdrawn
RosoxacinAlclofenac may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinAlclofenac may increase the neuroexcitatory activities of Rufloxacin.Experimental
SabarubicinAlclofenac may decrease the excretion rate of Sabarubicin which could result in a higher serum level.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Alclofenac.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Alclofenac.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Alclofenac.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Alclofenac.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Alclofenac.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Alclofenac.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Alclofenac.Approved
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Alclofenac.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Alclofenac.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Alclofenac.Investigational
SisomicinAlclofenac may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinAlclofenac may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Alclofenac.Approved
SotalolAlclofenac may decrease the antihypertensive activities of Sotalol.Approved
SP1049CAlclofenac may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinAlclofenac may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpectinomycinAlclofenac may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Alclofenac.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Alclofenac.Investigational
StreptomycinAlclofenac may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinAlclofenac may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Alclofenac.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Alclofenac.Approved
SulodexideAlclofenac may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Alclofenac.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Alclofenac.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Alclofenac is combined with Suxibuzone.Experimental
TacrolimusAlclofenac may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Alclofenac.Approved
TalinololAlclofenac may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Alclofenac.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Alclofenac.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Alclofenac.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Alclofenac is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Alclofenac is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Alclofenac.Approved, Investigational
TemafloxacinAlclofenac may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Alclofenac.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Alclofenac is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Alclofenac is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Alclofenac.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Alclofenac.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Alclofenac.Approved
TertatololAlclofenac may decrease the antihypertensive activities of Tertatolol.Experimental
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Alclofenac.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Alclofenac is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololAlclofenac may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Alclofenac.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Alclofenac is combined with Tixocortol.Approved, Withdrawn
TobramycinAlclofenac may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Alclofenac.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Alclofenac.Approved
TorasemideAlclofenac may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Alclofenac.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Alclofenac.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Alclofenac.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Alclofenac.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Alclofenac is combined with Triamcinolone.Approved, Vet Approved
TriamtereneAlclofenac may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Alclofenac is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Alclofenac.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Alclofenac.Investigational
TrovafloxacinAlclofenac may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinAlclofenac may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Alclofenac is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Alclofenac.Approved, Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Alclofenac.Investigational, Withdrawn
ValrubicinAlclofenac may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Alclofenac.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Alclofenac.Approved
WarfarinAlclofenac may increase the anticoagulant activities of Warfarin.Approved
XimelagatranAlclofenac may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Alclofenac.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Alclofenac.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Zofenopril is combined with Alclofenac.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Alclofenac is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Alclofenac.Withdrawn
Zoptarelin doxorubicinAlclofenac may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level.Investigational
ZorubicinAlclofenac may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
Not Available

References

General References
  1. Wiggins LF: The chemical and biological background to alclofenac. Curr Med Res Opin. 1975;3(5):241-8. [PubMed:241593]
  2. Lambotte F: Therapeutic activity of 4-allyloxy-3-chlorophenylacetic acid. Arzneimittelforschung. 1970 Apr;20(4):569-71. [PubMed:4911592]
  3. Thomas GM, Rees P, Dippy JE, Maddock J: Simultaneous pharmacokinetics of alclofenace in plasma and synovial fluid in patients with rheumatoid arthritis. Curr Med Res Opin. 1975;3(5):264-7. [PubMed:241595]
  4. Selinsky BS, Gupta K, Sharkey CT, Loll PJ: Structural analysis of NSAID binding by prostaglandin H2 synthase: time-dependent and time-independent inhibitors elicit identical enzyme conformations. Biochemistry. 2001 May 1;40(17):5172-80. [PubMed:11318639]
  5. Brogden RN, Heel RC, Speight TM, Avery GS: Alclofenac: a review of its pharmacological properties and therapeutic efficacy in rheumatoid arthritis and allied rheumatic disorders. Drugs. 1977 Oct;14(4):241-59. [PubMed:21068]
External Links
KEGG Drug
D01252
PubChem Compound
30951
PubChem Substance
347829274
ChemSpider
28714
ChEBI
31183
ChEMBL
CHEMBL94081
Wikipedia
Alclofenac
ATC Codes
M01AB06 — Alclofenac

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.288 mg/mLALOGPS
logP3.01ALOGPS
logP2.79ChemAxon
logS-2.9ALOGPS
pKa (Strongest Acidic)3.71ChemAxon
pKa (Strongest Basic)-4.9ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area46.53 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity57.8 m3·mol-1ChemAxon
Polarizability22.28 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenol ethers. These are aromatic compounds containing an ether group substituted with a benzene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Phenol ethers
Sub Class
Not Available
Direct Parent
Phenol ethers
Alternative Parents
Phenoxy compounds / Chlorobenzenes / Alkyl aryl ethers / Aryl chlorides / Monocarboxylic acids and derivatives / Carboxylic acids / Organochlorides / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Phenoxy compound / Phenol ether / Alkyl aryl ether / Chlorobenzene / Halobenzene / Aryl chloride / Monocyclic benzene moiety / Aryl halide / Monocarboxylic acid or derivatives / Ether
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
aromatic ether, monocarboxylic acid, monochlorobenzenes (CHEBI:31183)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Thomas GM, Rees P, Dippy JE, Maddock J: Simultaneous pharmacokinetics of alclofenace in plasma and synovial fluid in patients with rheumatoid arthritis. Curr Med Res Opin. 1975;3(5):264-7. [PubMed:241595]

Drug created on February 11, 2017 11:07 / Updated on December 01, 2017 16:38